Authors' Reply

J Mol Diagn. 2018 Mar;20(2):266. doi: 10.1016/j.jmoldx.2017.12.001.

¹ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.
² INSERM U1245 Team 03, Centre Henri Becquerel, Rouen. Electronic address: philippe.ruminy@chb.unicancer.fr.
³ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Pathology, Centre Henri Becquerel, Rouen.
⁴ LITIS (Laboratoire d'Informatique et de Traitement de l'Information), EA 4108, UNIROUEN, University of Normandie, Rouen.
⁵ INSERM UMRS 872, AP-HP (Assistance Publique-Hopitaux de Paris) Necker Hospital, Paris.
⁶ Functional Genomics Platform, Center for Biology and Pathology, University of Lille, Lille; Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁷ Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁸ Department of Hematology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Benite, Lyon.
⁹ Lymphoid Malignancies Unit, Hospital Henri Mondor, Creteil.
¹⁰ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Biological Hematology, Rouen University Hospital, Rouen.

Abstract

Authors' Reply to the Letter to the Editor by Y. Lynn Wang (MYD88 mutations and sensitivity to ibrutinib therapy).